Publications by authors named "Laurie-Anne Bertholon"
Cerebrospinal fluid (CSF) biomarkers are used to diagnose Alzheimer disease (AD), especially in atypical clinical presentations. No consensus currently exists regarding cut-off values. This study aimed, firstly, to define optimal cut-off values for CSF biomarkers, and secondly, to investigate the most relevant diagnostic strategy for AD based on CSF biomarker combinations.
View Article and Find Full Text PDFArticle Synopsis
- * This study involved 250 patients over 65 years old and examined the potential link between frailty and protein molecular aging markers, specifically focusing on post-translational modification derived products (PTMDPs).
- * The results showed that frail patients had higher levels of certain PTMDPs, particularly homocitrulline (HCit) and advanced glycation end-products measured by skin autofluorescence (SAF), suggesting these could serve as effective biomarkers for identifying frailty in elderly patients.
Background: A high anticholinergic burden (AB) is associated with the occurrence of behavioral and psychological symptoms (BPSDs), which are frequent in dementia.
Objectives: Our aim was to determine the threshold for a reduction in AB that would lead to a clinically significant improvement in BPSDs (in terms of frequency, severity, and disruptiveness).
Design: A single-center prospective study.
The complement receptor 1 () gene was shown to be involved in Alzheimer's disease (AD). We previously showed that AD is associated with low density of the long CR1 isoform, CR1*2 (S). Here, we correlated phenotype data (CR1 density per erythrocyte (CR1/E), blood soluble CR1 (sCR1)) with genetic data (density/length polymorphisms) in AD patients and healthy controls.
View Article and Find Full Text PDFObjective: The aim of this study was to evaluate the impact of a reduction of the anticholinergic burden (AB) on the frequency and severity of behavioral and psychological symptoms of dementia (BPSD) and their repercussions on the care team (occupational disruptiveness).
Methods: In this prospective, single-center study in an acute care unit for Alzheimer disease (AD) and related disorders, 125 elderly subjects (mean age: 84.4 years) with dementia presented with BPSD.